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CC BY-NC-ND license (http://creativeBackground/purpose: Clinical implications of IL28B gene in Taiwanese chronic hepatitis C
(CHC) patients remain unknown. We thus investigated the prevalence and clinical implications
of IL28B rs8099917 genotypes in CHC patients with different hepatitis C virus (HCV) genotypes
and healthy controls.
Methods: A total of 200 HCV genotype 1 patients and 200 HCV genotype 2 patients who
received liver biopsy, as well as 197 healthy controls were enrolled to determine the fre-
quencies of IL28B rs8099917 genotypes. In addition, the association of IL28B rs8099917 geno-
type with baseline data, including HCV RNA level, HCV genotype, histological activity grade,
fibrosis stage, and body mass index, were evaluated and further stratified by covariant factors.
Results: Compared with healthy controls, CHC patients had a lower prevalence rate of favor-
able IL28B rs8099917 TT genotype (81.0% vs. 89.3%, p Z 0.025). In addition, the prevalencenflict of interest for this article.
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954 Y.-H. Mah et al.rates of favorable TT genotype in patients with HCV genotypes 1 and 2 were 76.0% and 86.0%,
respectively (pZ 0.007). Using ordered logistic regression analysis, higher fibrosis stages were
found to be associated with a lower prevalence of TT genotype (p Z 0.033), but not histolog-
ical activity grades (p Z 0.748). The association with fibrosis stages was more pronounced in
female patients (p Z 0.024).
Conclusion: In Taiwan, CHC patients have a lower frequency of favorable IL28B TT genotype
than healthy controls. Among patients with CHC, the frequency of TT genotype is higher in
HCV genotype 2 patients than in HCV genotype 1 patients. In addition, CHC patients with TT
genotype, particularly females, have a lower likelihood of advanced fibrosis.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Hepatitis C virus (HCV) infection is a global health problem,
with more than 3% of the world population being infected
with HCV.1 It is estimated that up to 80% of acutely infected
individuals fail to clear the virus and then develop chronic
hepatitis C (CHC),2 with as many as 5% of them eventually
progressing to end-stage liver disease including liver can-
cer.3 Prevention of acute HCV infection and timely effec-
tive treatment of chronic HCV infection are the mainstay
for the global control of HCV infection.4 Over the past
decade, successful treatment with pegylated interferon
plus ribavirin (pegIFN/RBV) depends on HCV genotypes and
the strategy of response-guided therapy, with the sustained
viral response rate (SVR) of 50e80%.5,6 More potent direct
acting antivirals with safer profiles have been developed.7,8
In the era of interferon-free regimen, treatment options for
CHC have become more and more personalized. Eradication
of HCV has been confirmed to reduce liver-related as well
as all-cause mortality and morbidity.4,9e11
The prognosis of HCV is directly related to the restless
accumulation of extracellular fibrotic tissue in the liver,
which, eventually, alters the liver architecture and its
vascularization, leading to the development of cirrhosis and
related complications. The factors known to substantially
contribute to more rapid disease progression include
alcohol abuse, viral coinfections, host risk factors, failure
to respond to antiviral treatment, male gender,12
ethnicity,13 insulin resistance,14 obesity, immunity,15,16
advanced fibrosis, and hepatic steatosis.17
Several genome-wide association studies have identified
the rs1297986018,19 and rs8099917 single-nucleotide poly-
morphisms (SNPs)20,21 on chromosome 19q13.13 near the
IFNL3 gene (formerly known as IL28B) as variants associ-
ated with both response to pegIFN/RBV treatment in pa-
tients with HCV genotype 1 (HCV-1) infection18,20e23 and
spontaneous HCV clearance.22e24 A strong predictive value
of the IL28B polymorphism is only observed in HCV-1 and
HCV-4 patients, but not in HCV-2 and HCV-3 patients.22
These studies clearly documented that IL28B rs12979860
or rs8099917 are the polymorphisms most significantly
associated with the response to pegIFN/RBV therapy. These
two SNPs are in strong linkage disequilibrium except in
patients of African ancestry; they are in partial linkage
disequilibrium in Caucasians,18,22 but in near-complete
linkage disequilibrium in East Asians.17 Among the SNPs,rs12979860 CC genotype or rs8099917 TT genotype is the
favorable genotype.18e21
In Taiwan where chronic HCV infection is endemic,
available data regarding the strength of genetic marker
association as well as the prevalence of IL28B genotype and
its correlation with clinical manifestations in CHC patients
remain limited.25e27 In this study, we thus determined the
prevalence rate of IL28B rs8099917 genotype in CHC pa-
tients and healthy controls. In addition, the association of
IL28B rs8099917 genotype with baseline data, including HCV
RNA level, HCV genotype, histological activity grade,
fibrosis stage, and body mass index in CHC patients, was
explored.Materials and methods
Patients
The study design was cross sectional and observational.
This study was conducted in consecutive patients with CHC
who underwent a diagnostic liver biopsy at the National
Taiwan University Hospital from 2005 to 2011. The inclusion
criteria were as follows: (1) serologic evidence of CHC
defined by the presence of anti-HCV antibody (Abbott HCV
EIA 3.0; Abbott Laboratories, Abbott Park, IL, USA) and
serum HCV RNA by real-time polymerase chain reaction
analysis (Cobas TaqMan HCV Test v2.0; Roche Diagnostics
GmbH, Mannheim, Germany; limit of detection 15 IU/mL)
for 6 months; (2) a biopsied liver tissue of adequate size
for fibrosis staging (>15 mm with more than 7 portal
tracts); (3) confirmed human genomic DNA for IL28B
rs8099917 polymorphism analysis; and (4) confirmed and
properly recorded patient baseline data including age, sex,
body mass index, serum aspartate aminotransferase (AST),
alanine aminotransferase (ALT) level, HCV RNA level, HCV
genotype (Inno-LiPA HCV II; Innogenetics, Ghent, Belgium),
staging of hepatic fibrosis by METAVIR score (F0eF4),28 and
grading of histological activity by METAVIR score.28 Patients
infected with hepatitis B virus, human immunodeficiency
virus, Type II diabetes or severe obesity/metabolic syn-
drome (body mass index> 32), Wilson’s disease, autoim-
mune hepatitis, primary biliary cirrhosis, sclerosing
cholangitis, alpha-1-antitrypsin deficiency, decompensated
cirrhosis, overt hepatic failure, and a current or past history
of alcohol abuse (20 g daily) were excluded, in order to
Table 1 Clinical characteristic of the study population.
Characteristics HCV patients (N Z 400) Healthy controls (N Z 197) p
Mean (SD) or no. (%) Mean (SD) or no. (%)
Age (y) 53.89 (11.8) 51.83 (9.8) 0.0255
Male (%) 184 (46.0) 53 (26.9) <0.001
Body mass index (kg/m2) 25.51 (3.77) 23.45 (3.46) <0.001
AST (U/L) 93.9 (63.7) 23.5 (10.4) <0.001
ALT (U/L) 136.7 (101.6) 24.0 (16.1) <0.001
HCV RNA log10 (IU/mL) 5.88 (0.88)
Histological activity grade (by MEDAVIR score)
1 213 (53.3)
2 135 (33.8)
3 44 (11.0)
Unknown 8
Hepatic fibrosis stage (by MEDAVIR score)
1 88 (22.0)
2 140 (35.0)
3 55 (13.8)
4 108 (27.0)
Unknown 9
HCV genotype
1a 23 (5.75)
1b 177 (44.25)
2a 150 (37.50)
2b 50 (12.50)
ALT Z alanine aminotransferase; AST Z aspartate aminotransferase; HCV Z hepatitis C virus; SD Z standard deviation.
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profound effect on disease progression in CHC.
A total of 200 HCV-1 patients, 200 HCV-2 patients, and
197 healthy controls were enrolled. All of them are
Taiwanese. The main clinical characteristics of the study
population are shown in Table 1. All HCV patients received
liver biopsy for the staging of hepatic fibrosis and histo-
logical activity. The analysis of association between genetic
polymorphism and disease severity was adjusted by sex,
age, body mass index, AST and ALT, HCV RNA level, HCV
genotype, fibrosis stage, and histological activity grade.
None of our CHC patients had received antiviral treatment
prior to the inclusion into this study.
SNP genotyping
Human genomic DNA was extracted from the peripheral
blood mononuclear cells by QIAamp kits (Qiagen, Inc.,
Valencia, CA, USA). IL28B rs8099917 genotypes, including
homozygous TT, heterozygous GT, and homozygous GG ge-
notypes, were analyzed by the ABI TaqMan allelic discrim-
ination kit and the ABI7900HT Sequence Detection System
(Applied Biosystem, Life Technologies Corporation, Grand
Island, NY, USA) as previously described.29,30
Ethical considerations
This study was approved by the local Ethical Committee and
was conducted according to the ethical guidelines of the
1975 Declaration of Helsinki and International Conference
on Harmonization for Good Clinical Practice. All patientsand healthy controls gave informed consent to participate
in the study.
Liver biopsy
In all CHC patients, liver biopsy had been obtained using
the Menghini technique with a 1.6 mm needle. The median
biopsy length was 15 mm, and the median number of portal
tract was 7. An independent pathologist who was blinded to
genetic screening, and demographic and clinical data car-
ried out the biopsies. Fibrosis and histological staging were
defined using the METAVIR scoring system.28
Statistical analysis
The selected characteristics, METAVIR fibrosis stages, his-
tologic activity, and HCV genotypes were presented as
means (standard deviations) or numbers (percent), and the
statistical comparison between CHC patients and healthy
controls was performed by t test with equal or unequal
variance or c2 tests, whenever appropriate. An uncondi-
tional logistic regression model was used to estimate the
odds ratios and 95% confidence intervals of the association
between CHC and IL28B rs8099917 genotypes. The adjust-
ment variables in this model included age, gender, body
mass index, AST, and ALT. Among CHC patients, ordered
logistic regression or binary logistic regression models were
conducted to investigate the relationships between HCV
genotypes (4 subtypes and 2 major types), METAVIR fibrosis
stages (3 categories), METAVIR histologic activity (3 cate-
gories), and IL28B rs8099917 genotypes, whenever
Table 2 Genotype and allele frequencies of IL28B rs8099917 in CHC patients and healthy controls.
IL28B CHC patients
(N Z 400)
Healthy controls
(N Z 197)
Crude OR
(95% CI)
p Adjusted ORa
(95% CI)
p Adjusted ORb
(95% CI)
p
No. (%) No. (%)
rs8099917
GG 7 (1.8) 0 (0.0) 1.00 (reference) 1.00 (reference) 1.00 (reference)
GT 69 (17.3) 21 (10.7)
TT 324 (81.0) 176 (89.3) 0.51 (0.30e0.85) 0.01 0.54 (0.31e0.93) 0.025 0.98 (0.39e2.46) 0.962
G allele 83 (10.4) 21 (5.3) 1.00 (reference) 1.00 (reference) 1.00 (reference)
T allele 717 (89.6) 373 (94.7) 0.49 (0.30e0.80) 0.004 0.52 (0.31e0.87) 0.013 0.82 (0.35e1.90) 0.639
ALTZ alanine aminotransferase; ASTZ aspartate aminotransferase; CHCZ chronic hepatitis C; CIZ confidence interval; ORZ odds
ratio.
a Adjusted for age, gender, and body mass index.
b Adjusted for age, gender, body mass index, AST, and ALT.
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index, AST, ALT, HCV RNA viral load, HCV genotype, and
fibrosis stages/histological activity were included as
adjustment variables. Statistical significance was deter-
mined by two-tailed tests, and all statistical analyses were
performed using Stata (Version 12.1; Stata Corp., College
Station, TX, USA).Results
Baseline characteristic of patients
A total of 400 HCV patients (200 HCV-1 and 200 HCV-2 pa-
tients) were enrolled (Table 1). There were 184 (46%) male
and 216 (54%) female HCV patients, with a mean age of
53.9þ 11.8 years (mean standard deviation) at the time
of biopsy. The mean body mass index of the patients was
25.5þ 3.8 (mean standard deviation). The mean AST and
ALT levels were 93.9þ 63.7 U/L and 136.7þ 101.6 U/L,
respectively, at the time of biopsy. The mean HCV RNA
level was 5.9 0.9 log10 IU/mL. The findings of histological
activity grading were as follows: Stage 1 in 213 (53.3%),
Stage 2 in 135 (33.8%), and Stage 3 in 44 (11.0%) patients.
Regarding the stage of hepatic fibrosis, we found StagesTable 3 Association between genotype frequencies of IL28B rs
patients.
IL28B
rs8099917
HCV subtype
1a
(N Z 23)
1b
(N Z 177)
2a
(N Z 150)
2b
(N Z 50)
GG 0 (0.0%) 3 (1.7%) 2 (1.3%) 2 (4.0%)
GT 3 (13.0%) 42 (23.7%) 21 (14.0%) 3 (6.0%)
TT 20 (87.0%) 132 (74.6%) 127 (84.7%) 45 (90.0%
HCV genotype 1
(N Z 200)
HCV genotype 2
(N Z 200)
GG/GT 48 (24.0%) 28 (14.0%)
TT 152 (76.0%) 172 (86.0%)
Odds ratio was constructed considering unfavorable genotype GG/GT
CI Z confidence interval; HCV Z hepatitis C virus; OR Z odds ratio.
a Based on logistic regression with binary HCV genotype 1 versus 2.0e1 in 88 (22%), Stage 2 in 140 (35%), Stage 3 in 55 (13.8%),
and Stage 4 in 108 (27%) patients. The HCV genotype and
subgenotype were determined in all 400 HCV patients, and
were found to be HCV-1a in 23 (5.75%), HCV-1b in 177
(44.25%), HCV-2a in 150 (37.50%), and HCV-2b in 50 (12.50%)
patients.
In this study, there were 197 healthy controls with a
mean age of 51.8 9.8 years. The number of males was 53
(26.9%). The mean body mass index was 23.5 3.5. The
mean ALT and AST levels were 23.5 10.4 U/L and
24.0 16.1 U/L, respectively.Genotype and allele frequencies of IL28B
rs8099917 in CHC patients and controls
The genotype and allele frequencies of IL28B rs8099917
polymorphism in 400 CHC patients and 197 healthy controls
differed significantly (Table 2). Compared with healthy
controls, CHC patients had a lower prevalence rate of
favorable IL28B rs8099917 TT genotype (81.0% vs. 89.3%,
p Z 0.025) after adjustment for age, gender, and body
mass index. However, the p value became 0.962 after
adjustment for age, gender, body mass index, AST, and ALT.
We also found a lower prevalence rate of T allele in CHC8099917 and HCV genotypes/subtypes in chronic hepatitis C
Crude OR (95% CI) p Adjusted OR
(95% CI)
p
1.00 (reference) 1.00 (reference)
) 1.72 (1.08e2.75) 0.023 1.81 (1.11e2.96) 0.017
1.00 (reference) 1.00 (Reference)
1.94a (1.16e3.25) 0.012 2.17a (1.24e3.81) 0.007
as reference.
Table 4 Association between genotype frequencies of IL28B rs8099917 and hepatic fibrosis stages in chronic hepatitis C
patients.
IL28B
rs8099917
Hepatic fibrosis by METAVIR score Crude OR
(95% CI)
p Adjusted ORa
(95% CI)
p
Stage 1
(N Z 88)
Stage 2
(N Z 140)
Stage 3
(N Z 55)
Stage 4
(N Z 108)
GG 1 (1.1%) 0 (0.0%) 2 (3.6%) 2 (1.9%)
GT 14 (15.9%) 16 (11.4%) 9 (16.4%) 30 (27.8%) 1.00 (reference) 1.00 (reference)
TT 73 (83.0%) 124 (88.6%) 44 (80.0%) 76 (70.4%) 0.50 (0.31e0.80) 0.004 0.57 (0.34e0.96) 0.033
Odds ratio was constructed considering unfavorable genotype GG/GT as reference.
ALT Z alanine aminotransferase; AST Z aspartate aminotransferase; CI Z confidence interval; HCV Z hepatitis C virus; OR Z odds
ratio.
a Adjusted for age, gender, body mass index, AST, ALT, HCV RNA viral load, HCV genotype, and histological activity.
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age, gender, and body mass index.
Genotype frequencies of IL28B rs8099917 in CHC
patients stratified by HCV genotype and
subgenotype
The prevalence rates of favorable TT genotype in HCV-1
and HCV-2 patients were 76.0% and 86.0%, respectively
(p Z 0.007; Table 3). In addition, the favorable TT geno-
type was highest in HCV-2b patients (90.0%) and lowest in
HCV-1b patients (74.6%), and the unfavorable GG/GT ge-
notype was highest in HCV-1b patients (25.4%) and lowest in
HCV-2b patients (10.0%) (p Z 0.017; Table 3)
Genotype frequencies of IL28B rs8099917 in CHC
patients stratified by hepatic fibrosis stages and
histological activity grades
Using ordered logistic regression analysis, the prevalence
rates of favorable TT genotype among patients with MET-
AVIR fibrosis Stages 1, 2, 3, and 4 were 83.0%, 88.6%, 80.0%,
and 70.4%, respectively (pZ 0.033; Table 4). Furthermore,
CHC patients with the favorable TT genotype had a lower
likelihood of developing advanced fibrosis than those with
unfavorable GG or GT genotype (Table 4). However, the
prevalence rate of TT genotype was not associated with
histological activity grades (Table 5). Further analysis
showed that female CHC patients with TT genotype had aTable 5 Association between genotype frequencies of IL28B rs8
patients.
IL-28B
rs8099917
Histological activity by METAVIR score C
Grade 1
(N Z 213)
Grade 2
(N Z 135)
Grade 3
(N Z 44)
GG 3 (1.4%) 3 (2.2%) 0 (0.0%)
GT 36 (16.9%) 25 (18.5%) 5 (11.4%) 1
TT 174 (81.7%) 107 (79.3%) 36 (81.8%) 0
Odds ratio was constructed considering unfavorable genotype GG/GT
ALT Z alanine aminotransferase; AST Z aspartate aminotransf
OR Z odds ratio.
a Adjusted for age, gender, body mass index, AST, ALT, HCV RNA vilower likelihood of developing advanced hepatic fibrosis
than male patients (p Z 0.024; Table 6). In the overall
cohort, we found no association between METAVIR histo-
logical activity of hepatitis and IL28B genotype distribution.
Discussion
Polymorphisms related to the gene encoding IL-28B are the
strongest baseline factors predictive of the HCV clearance,
either interferon induced or spontaneous.18e24 IL28B be-
longs to the interferon-lambda family and plays a plausible
biological role in antiviral defense.31 The predictive ca-
pacity of IL28B is, thus far, strongest for patients with HCV-
1 or HCV-4 infection.19,32,33 IL28B homozygote for the
favorable allele is linked to rapid viral response.19,34 In the
United States, the favorable C allele at rs12979860 or T
allele at rs8099917 was positively associated with SVR. In
patients of European ancestry, 80% of those with the
favorable rs12979860 CC genotype or rs8099917 TT geno-
type cleared the virus, whereas only 30% of those with
unfavorable genotype did so. The favorable genotype was
also more common in European Americans (39%) than in
African Americans (16%).27 The difference in the allele
frequency explains approximately half of the difference in
the response rate between patients of African American
versus those of European ancestry, indicating that genetic
background is more important than ethnicity.18,20,27
In this study, we demonstrated that the allele and ge-
notype frequency of rs8099917 differed between CHC099917 and histological activity grades in chronic hepatitis C
rude OR (95% CI) p Adjusted ORa
(95% CI)
p
.00 (reference) 1.00 (reference)
.92 (0.57e1.49) 0.735 1.09 (0.65e1.82) 0.748
as reference.
erase; CI Z confidence interval; HCV Z hepatitis C virus;
ral load, HCV genotype, and fibrosis stages.
Table 6 Odds ratios and 95% confidence intervals of genotype frequencies of IL28B rs8099917 in relation to hepatic fibrosis
stages and histological activity grades in chronic hepatitis C patients stratified by gender.
IL-28B Fibrosis stage Histological activity grade
Males
(N Z 184)
Females
(N Z 216)
Males
(N Z 184)
Females
(N Z 216)
Adjusted ORa
(95% CI)
p Adjusted ORa
(95% CI)
p Adjusted ORb
(95% CI)
p Adjusted ORb
(95% CI)
p
rs8099917
GG/GT 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
TT 0.80 (0.35e1.86) 0.611 0.46 (0.24e0.91) 0.024 1.65 (0.63e4.33) 0.369 1.01 (0.51e2.00) 0.968
Odds ratio was constructed considering unfavorable genotype GG/GT as reference.
ALT Z alanine aminotransferase; AST Z aspartate aminotransferase; CI Z confidence interval; HCV Z hepatitis C virus; OR Z odds
ratio.
a Adjusted for age, gender, body mass index, AST, ALT, HCV RNA viral load, HCV genotype, and histological activity.
b Adjusted for age, gender, body mass index, AST, ALT, HCV RNA viral load, HCV genotype, and fibrosis stages.
958 Y.-H. Mah et al.patients and healthy controls. Healthy controls had a higher
frequency of favorable rs8099917 TT genotype (89.3%) than
CHC patients (81.0%), whereas CHC patients had a higher
frequency of unfavorable GG or GT genotype than healthy
controls (p< 0.025), suggesting that the presence of
favorable T allele might have a protective effect against
HCV infection. These findings were consistent with previous
reports that the favorable allele is associated with a higher
probability of clearing virus during the natural history of
chronic HCV infection.35,36 We also found a higher fre-
quency of favorable rs8099917 TT genotype in patients with
HCV-2 versus HCV-1 infection (p< 0.012). In addition, the
unfavorable GG or GT genotype was detected at an
increased frequency in patients with HCV-1 infection
compared with those with HCV-2 infection. Previous studies
also indicated that the unfavorable rs12979860 genotype is
more frequent in HCV-1 patients.35e37 We also found no
association between METAVIR histological activity of hepa-
titis and IL28B genotype distribution. However, more
advanced histological activity was found in patients car-
rying the favorable IL28B TT genotype compared with other
IL28B subgroups (TT vs. GT/GG) (p Z 0.748). A similar
finding was also noted in a recent study by D’Ambrosio
et al,38 who mentioned that there was no association be-
tween METAVIR histological activity of hepatitis and IL28B
genotype distribution, with the exception of more severe
portal infiltrates in HCV-1 patients carrying the favorable
IL28B CC genotype compared with other IL28B subgroups
[CC vs. CT/TT: 86% vs. 63%, odds ratio (95% confidence in-
terval): 3.24 (1.23e8.51), p Z 0.005]. Taking these data
together, the association of HCV genotype with IL28B
rs8099917 polymorphism may not be random. However, the
biological implications of this correlation await further
examinations.
The severity of hepatic fibrosis has been shown to
adversely affect the response to pegIFN/RBV.39,40 In this
study, a strong association between IL28B and hepatic
fibrosis was demonstrated. We found that the favorable
rs8099917 TT genotype had a protective effect against
advanced hepatic fibrosis, especially in female patients.
These data suggested that male HCV patients with an un-
favorable IL28B genotype could receive treatment earlier.In contrast, there is no association between rs8099917 ge-
notype and histological activity index.
Treating CHC with pegylated interferon plus weight-
based ribavirin shows a sustained virological response (SVR)
rate in approximately 50e70% of genotype 1 CHC patients
and an SVR in 70e90 % of genotype 2 CHC patients.25,41e43
Similar data were found from some other Asian countries
where the frequency of favorable IL28B genotype was
similar to that of Taiwan.41,44 For Asian HCV-1 patients,
those with the favorable IL28B genotype have a higher rapid
virological response (RVR) rate, which further predicts a
higher SVR rate to pegIFN/RBV therapy.41,45e50 Subgroup of
these patients with low baseline viral load can further
truncated the treatment duration to 24 weeks without
compromising the SVR rate.51,52 In contrast to HCV-1 pa-
tients without RVR, the viral decline beyond Week 4 of
therapy, rather than IL28B genotypes, is the key determi-
nant for SVR rate.30 HCV genotype 2/3 Asian patients with a
favorable IL28B genotype also tend to have a higher SVR
rate than those with unfavorable genotypes.53 Treatment
duration can be truncated to 12e16 weeks for HCV 2/3
Asian patients with RVR, irrespective of IL28B genotypes.
However, HCV 2/3 patients who fail to achieve RVR may
extend the treatment duration to 48 weeks if they have
unfavorable IL28B genotypes.25
In summary, Taiwanese CHC patients have a lower fre-
quency of favorable IL28B rs8099917 TT genotype than
healthy controls, and the frequency of TT genotype is
higher in HCV-2 than in HCV-1 patients. In addition, CHC
patients with favorable TT genotype, especially in females,
have a lower likelihood of advanced hepatic fibrosis.
Whether IL28B genotyping is of help for optimizing HCV
treatment, especially in the era of direct acting antivirals,
awaits further studies.References
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